Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
07 2019
Historique:
received: 20 10 2018
revised: 21 01 2019
accepted: 31 01 2019
pubmed: 28 4 2019
medline: 22 9 2020
entrez: 28 4 2019
Statut: ppublish

Résumé

End-stage renal disease (ESRD) of undetermined etiology is highly prevalent and constitutes a significant clinical challenge, particularly in the context of kidney transplantation (KT). Despite the identification of numerous rare hereditary nephropathies over the last few decades, patients with undetermined ESRD are not being systematically investigated for rare genetic causes in clinical practice. To address this, we utilized mutation analysis in patients on the kidney transplant waitlist and scrutinized underlying renal diagnoses of 142 patients in a single center KT-waitlist. This cohort was stratified into 85 cases of determined and 57 cases of undetermined ESRD. The latter patients were analyzed by a renal gene panel for mutations in 209 genes associated with ESRD. The most likely genetic diagnoses in 12% of the tested individuals with undetermined ESRD were established. All of these patients showed mutations in genes encoding components of the glomerular filtration barrier. Taken together, hereditary nephropathies, including autosomal dominant polycystic kidney disease, were identified in 35 of the 142 patients of the waitlist cohort. By significantly increasing the proportion of hereditary diagnoses from 29 to 35 patients, the rate of undetermined ESRD significantly decreased from 57 to 51 patients. This study demonstrates the beneficial use of genetic diagnostics in significantly unraveling undetermined ESRD cases prior to KT. Thus, in the absence of renal histology or the presence of unspecific histological conditions, such as hypertensive nephrosclerosis, focal segmental glomerulosclerosis or thrombotic microangiopathy, genetic analysis may provide a robust and specific renal diagnosis and allow for optimizing pre- and post-KT management.

Identifiants

pubmed: 31027891
pii: S0085-2538(19)30187-5
doi: 10.1016/j.kint.2019.01.038
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

222-230

Informations de copyright

Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Isabel Ottlewski (I)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Johannes Münch (J)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Timo Wagner (T)

Bioscientia, Institute of Human Genetics, Ingelheim, Germany.

Ria Schönauer (R)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Anette Bachmann (A)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Antje Weimann (A)

Department of Visceral, Transplant, Thoracic, and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.

Julia Hentschel (J)

Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany.

Tom H Lindner (TH)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany.

Daniel Seehofer (D)

Department of Visceral, Transplant, Thoracic, and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.

Carsten Bergmann (C)

Bioscientia, Institute of Human Genetics, Ingelheim, Germany; Department of Medicine, University Hospital Freiburg, Freiburg, Germany.

Rami Abou Jamra (RA)

Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany.

Jan Halbritter (J)

Division of Nephrology, Department of Internal Medicine, University Hospital Leipzig, Leipzig, Germany. Electronic address: jan.halbritter@medizin.uni-leipzig.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH